Tag: 137052-08-5

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137052-08-5,1-(Tetrahydro-2H-pyran-4-yl)ethanone,as a common compound, the synthetic route is as follows.

Add in a 50mL single-mouth bottle2-(5-Fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidine-4,5,6-triamine (0.11 g, 0.30 Mm),1-(tetrahydro-2H-pyran-4-yl)ethanone (0.050 g, 0.39 mmol) and methanol (10 mL),Acetic acid (0.17 mL, 3.0 mmol) was added at 0 C.After stirring at room temperature for 1 hour and then cooled to 0 C, sodium cyanoborohydride (0.094 g, 1.5 mmol) was added.It was then stirred at room temperature overnight.Evaporation of the solvent, EtOAc (EtOAc)The organic phase was washed with water (30 mL) and brine (30 mL)The residue was purified by silica gel column chromatography (dichloromethane/methanol (v/v) = 80/1, 0.5% triethylamine)A pale yellow solid (0.036 g, 25.0%)., 137052-08-5

137052-08-5 1-(Tetrahydro-2H-pyran-4-yl)ethanone 9877365, aTetrahydropyrans compound, is more and more widely used in various.

Reference£º
Patent; Guangdong Dongyangguang Pharmaceutical Co., Ltd.; Wang Xiaojun; Zuo Yinglin; Yu Chuan; Yang Chuanwen; Wang Jiancheng; Li Jing; Cao Shengtian; Wu Fangyuan; Zhang Yingjun; S ¡¤geerdeman; (79 pag.)CN108690016; (2018); A;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

137052-08-5, 1-(Tetrahydro-2H-pyran-4-yl)ethanone is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To 15 mL methanol were added 2-(7-fluoro-1-(2-fluorobenzyl)-1H-indazol-3 -yl)pyrimidine-4 ,5, 6-triamine (0.20 g, 0.54 mmol) and1-(tetrahydro-2H-pyran-4-yl)ethanone (0.10 g, 0.78 mmol). Then acetic acid (0.16 mL, 2.8 mmol)was added at 0 C. The mixture was heated to room temperature and stirred for 1 hour, thencooled to 0 C, and to the mixture was added sodium cyanoborohydride (0.17 g, 2.7 mmol).Then the resulting mixture was stirred at room temperature overnight. The reaction mixture wasconcentrated in vacuo to remove the solvent, and to the residue was added saturated aqueoussodium bicarbonate ( 40 mL ). The resulting mixture was extracted with ethyl acetate (30 mL x 2).The combined organic layers were washed with water (50 mL) and saturated brine (50 mL),dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated on a rotaryevaporator and the residue was purified by silica gel chromatograph ( dichloromethane /methanol(v/v) = 200/1, 0.5% triethylamine) to give a light yellow solid (0.11 g, 42.0%) MS (ESI, pos.ion) m/z: 480.7 (M+ 1);1H NMR (400 MHz, DMSO-d6) 8 (ppm) 8.56 (d, J = 8.0 Hz, 1H), 7.38-7.30 (m, 1H), 7.27- 7.19 (m, 2H), 7.19-7.09 (m, 2H), 6.97 (t, J = 7.0 Hz, 1H), 5.90 (s, 4H), 5.81 (s, 2H), 3.96-3.85 (m, 2H), 3.31-3.21 (m, 3H), 2.89-2.76 (m, 1H), 1.82- 1.74 (m, 1H), 1.72- 1.64 (m, 1H),1.64-1.51 (m, 1H), 1.40-1.26 (m, 2H), 0.95 (d, J= 6.4 Hz, 3H);19F NMR (376 MHz, DMSO-d6) 8 (ppm) -118.77 (d, J = 7.1 Hz), -134.46 (d, J = 7.1 Hz).

As the paragraph descriping shows that 137052-08-5 is playing an increasingly important role.

Reference£º
Patent; SUNSHINE LAKE PHARMA CO., LTD.; ZUO, Yinglin; WANG, Xiaojun; YANG, Chuanwen; WANG, Jiancheng; CAO, Shengtian; WU, Fangyuan; ZHANG, Yingjun; GOLDMANN, Siegfried; (193 pag.)WO2018/188590; (2018); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics